HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

9- (3- (2- nitro- 1- imidazolyl)- propylamino)cycopenteno(b)quinoline

PA refers to hydrochloride salt; structure given in first source

Also Known As:

NLCPQ-1

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Nitro Compounds: 66
  - Nitroimidazoles: 565
    - 9-(3-(2-nitro-1-imidazolyl)-propylamino)cycopenteno(b)quinoline: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Nitroimidazoles: 565
        9-(3-(2-nitro-1-imidazolyl)-propylamino)cycopenteno(b)quinoline: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - 9-(3-(2-nitro-1-imidazolyl)-propylamino)cycopenteno(b)quinoline: 1

Experts

1.	Bloomer, W D: 1 article (01/2003)
2.	Ji, M: 1 article (01/2003)
3.	Papadopoulou, M V: 1 article (01/2003)

Related Diseases

1.

Neoplasms (Cancer)

01/01/2003 - "The optimal degree of potentiation, P (percentage of tumor cells that were killed due to clear potentiation), was 31 and 33 when NLCPQ-1 was administered 2 h before CPM and 3-3.5 h after paclitaxel, respectively. "
01/01/2003 - "However, the results still suggest a potential clinical use of NLCPQ-1 as an adjuvant to CPM or paclitaxel therapy against solid tumors."
01/01/2003 - "At the above time schedules, NLCPQ-1 modified the dose of CPM and paclitaxel, for 60% tumor cell killing, by a factor of 1.8 and 2.1, respectively. "
01/01/2003 - "The antitumor effect of cyclophosphamide (CPM) and paclitaxel was investigated in BALB/c mice bearing EMT6 tumors, in combination with the bioreductive compound NLCPQ-1 by using the in vivo/in vitro assay as the endpoint. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Cyclophosphamide (Cytoxan)
3.	A-factor (Streptomyces)

Related Therapies and Procedures

1.	Therapeutics